While the number of sequenced genes is increasing dramatically, the number of different protein structural families is expected to be more limited. Changes in enzymatic activity or protein interactions can dramatically modify the role of homologous proteins in different organisms or mutants. However, experimental data associated with sequences or mutations stored in databases are often limited to a short description of the enzymatic pathway, molecular interaction or phenotype associated with the changes in amino acid sequence. In the alpha/beta-hydrolases fold database ESTHER, we are experimenting with links between experimental kinetic data and sequences, mutations and protein structures. This effort will lead to the integration of pharmacological data with genome-wide databases.
INTRODUCTION
With the advent of rapid genome sequencing, it has become apparent that the number of genes estimated for single organisms had been overestimated previously. Furthermore, it came as a surprise that the variation in the number of genes between multicellular model organisms is much less than expected. Of course the prediction of genes from genomic sequences is still in its infancy and many different proteins can result from alternative splicing. But although the number of sequences in databases will grow exponentially owing to the investigation of new model organisms, parasite mutants and variants of all kinds, there will not be a similar increase in the number of new sequences that are not related to a previously known family. Similarly, structural proteomics is expected to provide new structural folds mainly for proteins that are dif®cult to crystallise, such as membrane bound proteins. A great part of the observed diversity of chemical reactions, cellular specialisations and physiological adaptations are due to subtle differences in proteins, masked by the overall homology of their sequences or structures.
Gene and protein interactions give rise to a combinatorial complexity that is only now being investigated on a larger scale. The ®rst level is the genetic interactions as have been developed in the model organisms Drosophila and Caenorhabditis, but also in humans, farm animals and plants. These may be further studied mechanistically at the protein level. One can distinguish direct protein±protein interactions from more distant relationships, for example in the case of transcription factors and their target genes. The links can be even more distant in the case of hormonal neurotransmission regulation or in metabolic pathways. For enzyme functions, the critical factors are kinetic parameters as well as the concentration of substrates and regulators. Neither the enzyme concentration nor the level of gene expression necessarily affects the actual physiological condition.
Thus the challenge is to manage thē ow of information coming from the functional analysis of isolated proteins and from the large-scale analysis of gene expression. Databases have to develop easy-to-use and reliable tools for these new types of functional annotation. Comprehensive databases and servers such as PubMed Central or E-Biomed, which will give direct free access to experimental data, are an incentive to search for new ways of presenting biochemical data associated with gene sequences.
Since 1994, ESTHER, the alpha/beta hydrolase fold database, 1±4 has provided a server dedicated to presenting a wide variety of information related to this evergrowing family of proteins. 5±8 In this family, most proteins are enzymes for which a large number of natural and synthetic substrates or inhibitors are known. Most of the time, pharmacological data for these proteins are not available from sequence or gene databases.
In this paper we summarise some of the problems in the annotation of enzyme function in databases. Subsequently the paper aims to provide an overview of the ®rst attempts made in the ESTHER database to present enzyme kinetics data linked to mutation analysis in cholinesterases. Finally, future directions and expected limits are discussed.
DIFFICULTIES IN THE ANNOTATION OF ENZYME FUNCTION Large-scale analysis
Large-scale analysis of protein interactions or gene expression will not give all the clues necessary for deciphering the function of proteins of neurohumoral systems or enzymes. For example, the hypoglycaemic role of insulin in vivo would be dif®cult to deduce from the sequence homology of insulin with insulin-like growth factors. Furthermore, other knowledge such as the expression of the insulin gene in the pancreas, the protein's excretion in plasma and the ubiquitous interaction of insulin with receptors in tissues would also be of little help for the inference of the function of this hormone without physiological measurements.
In our case, for an enzyme such as acetylcholinesterase (AChE), protein interactions are important for the localisation of the enzyme but not for its activity. Among these protein interactions, ColQ of the collagen tail anchors the enzyme in the basal lamina at the neuromuscular junction, the P subunit binds the enzyme to the plasma membrane of neurones in the brain, and the proteins of the post-translational machinery add a glycolipid to the C terminus of the enzyme anchor in blood cells. 9 All these interactions are important for positioning the enzyme outside the cells, but are not involved directly in its function of acetylcholine hydrolysis. On the contrary, no direct protein interaction is seen between acetylcholinesterase and the acetylcholine receptors or cholinacetyltransferase, which provide the base of the functional cholinergic system. The expression pro®le is also misleading as acetylcholinesterase is often found in the same neurons as cholinacetyltransferase, leading to confusion of cholinergic and cholinoceptive neurons. Thus, how can a database present experimental data relevant for understanding the control of acetylcholine concentration by cholinesterases?
Proteins that do not participate in complex interactions give rise to other annotation problems including that the genes coding for these proteins are more prone to horizontal gene transfer between organisms. 10 Through such transfers, organisms not only may gain new functions, but also the newly acquired gene can evolve to participate in new pathways.
Proteins in the alpha/betahydrolase fold superfamily with very homologous 3D structures perform a wide variety of functions When the alpha/beta±hydrolase fold was ®rst de®ned and described, it was evident that this structure is widely represented in nature and that it serves to ful®l a great variety of enzymatic reactions. 5 The panel of reactions in which it is observed to participate has since then increased (see long range interactions impede from annotating enzyme function precisely Figure 1 ). 6±8 The enzyme reaction can be speci®c for a substrate found in the environment, eg xylane, cutine, lipids or proteins in the case of microorganism enzymes. The reaction can be less speci®c for extracellular or secreted enzymes in the case of eukaryotes, eg lipases or carboxylesterases. For those proteins that do not belong to a housekeeping pathway, true orthology in other taxonomic orders will be rare and comparison of sequences between organisms will be less informative. Another aspect of this variety is that a reaction performed by an alpha/betahydrolase fold protein may also be performed in another organism by a structurally unrelated enzyme. This has been shown to be the case for haloacetate dehalogenase, a member of the alpha/ beta-hydrolase fold superfamily.
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Proteins in the alpha/betahydrolase fold superfamily with very homologous sequences may have completely different functions It has been shown that apparent homologues of acetylcholinesterase have cell adhesion properties, but completely lack enzymatic activity. Among these, glutactin neurotactin and neurologins have all the landmarks of the alpha/betahydrolase fold, but not the activity. A model of the structure of neurotactin even shows what resembles an active site gorge, but without the active site amino acid necessary for esterase activity. There is not a clear motif for adhesion and another one for enzymatic activity; some may even have both properties. Without experimental testing, the only way to identify those proteins without enzymatic activity is the absence of key residues such as the active serine in a binding site motif. Many proteins have been wrongly classi®ed as esterases in the annotated genomes of C. elegans and Drosophila, since the annotation of such genes requires expertise that cannot be expected necessarily from the large-scale sequencing groups.
We try to bring some solutions to these dif®culties with a specialised database of alpha/beta-hydrolases fold named ESTHER. The restricted scope of the database allows the curators to focus on documenting the information from experimental data. 17 The information found in these databases can be extended to a higher degree of precision and include more sophisticated links for structure/ function analysis if a new database is dedicated to only a limited number of genes and proteins, as is done with the ESTHER database.
Structure of the ESTHER database
The database management system used for ESTHER is a well-known system used for genomic data ACeDB. 18 The interface of the database with the Internet is the webserver Perlace. 19 A general presentation of the database has been made previously. 4 Sequence and structure information in ESTHER is derived from the primary databases of GenBank, EBI and PDB, and direct links back to the original entries in these databases are available. Additionally, a collection of chemicals identi®ed as substrates or inhibitors of this family of enzymes has been introduced. The mutations and pharmacological data are extracted from the literature, and may now be submitted directly through forms on the World-Wide Web.
Linking mutation analysis to function
To date, at least 400 mutations have been studied in the cholinesterase family. Only a database can provide an ef®cient way to compare and analyse the results of these studies. In ESTHER we use different tools to present the mutation analysis of cholinesterases and provide links to enzyme kinetics.
The ®rst tool is Mutalign which provides a hypertext alignment of the cholinesterase sequences in which sitedirected or natural mutations have been analysed. Links between any mutated amino acid positions and experimental data obtained for the mutation can be selected and browsed from this web page. Symbols over each column of the alignment lead to combined information for mutations in all sequences at this similar position. This tool has been described previously, 4 but now the mutation pages also include kinetic data obtained on the mutated enzymes (see below).
The second tool is a mutation viewer written in Java that was developed originally to visualise mutations in the p53 gene and protein. 20 It allows a keyword search of mutation summaries and interactive displays in 1D, 2D and 3D of the AChE protein.
When the applet starts, four windows appear, of which three are representations of the AChE protein:
· A 1D view of the AChE protein is presented at two scales using à semantic lens'. The peptide sequence of the prototypic Torpedo californica AChE is readable in the lower part of the window.
· A 2D representation of the AChE protein with localisation of structural elements (see Figure 2 ).
· A 3D structure of Torpedo AchE as a wire frame representation that can be manipulated interactively with the mouse (rotation, zoom).
Included with the browser, a text area allows dialogue with the applet. For example, keywords listed in Table 1 may new tools to compare effects of mutations be entered here to perform a query. The last window presents the results of such a query (see Figure 2) . When search terms are entered into the query entry box in the browser window, the`hits' will be highlighted on the different representations of the AChE. For example when the term`Catalysis' is chosen, then the window with the secondary structure of ACHE will appear as shown in Figure 3 . The circles represent the position of amino acids that were mutated in order to study catalysis of AChE and they will appear with a similar colour in the primary and tertiary structure windows. When a single amino acid is selected, it is highlighted in red in all the displays, and details of the mutation and its effect are displayed in the text window (see Figure 3) .
We hope in the future to link the applet to the rest of the database and to be able to navigate from the viewer to the kinetic data pages.
Substrates and inhibitors
A collection of data on 300 inhibitors and 70 substrates is available from the database. For the moment, most of these are compounds speci®c to the cholinesterase subset of the database. Kinetic parameters obtained experimentally for 40 inhibitors and 36 substrates on 12 enzymes and 146 of their mutants have been collected. Shown in Figure 4 is a sample of the data collected for Tacrine, an inhibitor of acetylcholinesterase used for the treatment of Alzheimer's disease. The page includes the chemical structure and nomenclature, the kinetic parameters with summaries of experimental conditions, and references which are hypertext links to the details about the paper in which the experiment has been reported. Other links are available to pages about the mutations or the enzymes on which the inhibitor has been tested. When the mutation Y337A of mouse-acche (mouse acetylcholinesterase) is selected on this page, it gives the page presented in Figure  5 with the kinetic parameters determined for this particular mutation. A dictionary of terms is necessary to relate the sequence data to biological results. Objects associated with the sequence gene are obvious: mutations and amino acid changes. Parameters include Km, Kss, Kcat, Kapp, Ki, Ksi, Kon, Koff and Ic50. This nomenclature allows easy construction of queries using the query language available in ACeDB. A few terms have not yet been introduced as classes, but exist in text format and should in the future be indexed, eg temperature, ionic strength and enzyme concentration. Yet the vocabulary available already allows rational comparison of kinetic parameters for similar mutations in different organisms and multiple mutations in a unique sequence.
FUTURE DIRECTIONS
As with the general databases (eg GenBank, EBI, SWISS-PROT and PDB), the bottleneck for the development of the ESTHER database is the accurate entry of primary data and supplementary annotation. Facilitating the participation of individual scientists and laboratories in the submission of formatted data is of utmost priority. Data already in computer-readable formats in laboratories should be incorporated directly in the database, providing the appropriate conversion tools are available. Hopefully, it will soon be as common to submit such data as it is to submit sequence and structure data currently.
Ideally the end-users and their needs will direct the future development. Designs of new inhibitors, such as insecticides or therapeutic agents, could bene®t from the development of the ESTHER database. Protein engineering of cholinesterases and related enzymes is already an active ®eld with the design of biosensors with immobilised cholinesterases or decontaminating kinetic parameters in ESTHER developing tools to enrich the database Figure 3 : A text window describing the mutation selected on the secondary structure (see Figure 2) . Column 1 shows the query performed. Column 3 indicates that these mutations were made by site-directed mutagenesis (sdm). Column 4 describes the mutations using a numbering according to the species and the mutated enzyme. Column 5 is the torpedo_number, since AChE in different species shows some small variation in size, Torpedo AChE has been chosen as a typical AChE. Column 7 shows the effects of mutations and Column 8 is the bibliographic reference for each mutation devices for biological treatment of wastewater and hazardous waste. Improved lipases for food and household products is a very promising ®eld that necessitated a database of its own. 21 If such specialised databases correspond to a need, then practical actions will be necessary. Potentially, a thousand different types of protein fold implies a thousand individual databases for their characterisation. These will not all be of the same size, but those like the alpha/ beta-hydrolases database will require much more expertise and will need to be split into as many databases as there are functions or pathways ful®lled by proteins with this particular fold. The ESTHER database would become the merging of 10 to 20 individual subdatabases curated by specialists of each subfamily. The interconnection and the de®nition of standards for some thousands of databases with expert annotation may be the challenge of the years to come.
